FindTrial
Sign In

Langerhans cell histiocytosis (LCH): treatment protocol of the first international study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN97375227
Enrollment
Unknown
Registered
2001-07-01
Start date
1991-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma (non-Hodgkin's) Cancer Langerhans cell histiocytosis (LCH)

Interventions

1. Regimen A: Chemotherapy, vinblastine with high dose methyl prednisolone 2. Regimen B: Chemotherapy, etoposide with high dose methyl prednisolone

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Definitive diagnosis of multi-system Langerhans cell histocytosis 2. Age under 18 years 3. No prior treatment for Langerhans cell histocytosis

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026